

2 July 2018

NSX Announcement

Appointment of Director

Beroni Group Limited (NSX:BTG) (“Beroni” or the “Company”) is pleased to announce Dr. Zhinan Yin has been appointed as a Non-Executive Director of Beroni, effective 1 July 2018.

Dr. Zhinan Yin graduated from Hubei Medical University in 1984 and finished his Master’s Degree in Immunology from Shanghai Second Medical University in 1988. Dr. Yin went to the National Cancer Center of Italy to study and research on the immune mechanism of tumor cell metastasis and spread in 1992. Dr. Yin obtained his Doctorate degree with excellent results from the Free University of Berlin in 1997, and his academic dissertation won the Excellent Paper Award.

Dr. Zhinan Yin is an excellent scientist who has gained rich experience in the academic world in both US and China. Dr. Yin has over 30 years of working experience with a range of universities including Yale University, Nankai University and Jinan University. Dr. Yin’s main research area is the differentiation and development of $\gamma\delta$ T cells and their roles in the regulation of tumor immunity, hepatitis, and intestinal flora. Dr. Yin has published 103 academic articles, among which he is the first author, communication author, or co-corresponding author for 52 academic articles. Dr. Yin is a current Dean, Professor and PhD Tutor at Institute of Biomedical Transformation of Jinan University and Visiting Professor at Yale University School of Medicine.

Change of Chief Financial Officer

Beroni also advises that Mr Peter Wong has agreed to assume the role of Chief Financial Officer, replacing Mr Chris Deng with immediate effect. Mr Wong will become an Executive Director of the Company whilst Mr Deng remains as a Non-Executive director of the Company.

For further information please contact:

Mr Jacky Zhang
Executive Chairman
Tel: +86 1851 6931 911
E: 1710426553@qq.com

Mr Peter Wong
Executive Director
Tel: +61 423 727 580
E: pwong@asiainvest.com.au

About Beroni Group Limited (NSX: BTG) (FSE:6B9)

Beroni Group is a Chinese biotechnological company which is dual listed on the National Stock Exchange (Australia) and Frankfurt Stock Exchange. Its business mainly focuses on biotechnology, life sciences, environmental science and governance, precision medicine, regenerative medicine, and stem cell anti-cancer and anti-aging projects. Beroni Group’s overall strategic goal is to have a global presence in the biotechnology, bio-science and environmental science industries.